Disease pathways

FRET is an extremely useful phenomenon when it comes to the analysis of molecular conformations and interactions. F or the analysis of interactions, in which two separate molecules are labeled with an appropriate pair of fluorophores, an interaction can be shown by observing FRET. Further, FRET can be used as a type of spectroscopic ruler to measure the closeness of interactions. Proteins, lipids, enzymes, DNA, and RNA can all be labeled and interactions documented. This general method can be applied not only to questions of cellular function like kinase dynamics [3] but also to disease pathways, for example, the APP-PS1 interaction that is important in Alzheimer s disease (AD) [4], Alternatively, two parts of a molecule of interest can be labeled with a donor and acceptor fluorophore. Using this technique, changes in protein conformation and differences between isoforms of proteins can be measured, as well as protein cleavage. 

Clinical research groups are responsible for the discovery of new chemical entities, to target and interrupt disease pathways. It is common for drug products to come from families where the active backbone that targets the desired receptor is the same, and different side chains are added to achieve activity in the body. The development of thermodynamic methods that facilitate this approach will have an obvious advantage in reducing data requirements for the life science industries. 

Which disease pathway does the target regulate ... 

The main drug targets are enzymes, intracellular receptors, and extracellular (cell surface) receptors. Drugs are normally designed to interact with these entities either as agonists or antagonists to achieve control over the disease pathway. 

The next step is the screening of thousands of these compounds to hnd lead compounds or potential drug molecules that bind with receptors and modulate disease pathways. When an interaction happens, it is referred to as a hit. ... 

Predict binding sites for drug interactions and modulations of causative effects of disease pathway. 

Several approaches are utilized to study systems biology. The bottom-up approach starts from the molecular level, the omics, to identify and evaluate the genomic and proteomic basis of diseases. The top-down approach attempts to integrate human physiology and diseases to provide models to understand disease pathways at organ levels. 

Metabolomics and systems biology are new fields of study to better understand diseases and disease pathways. These new studies may help to discover and develop more effective drugs with fewer adverse reactions in shorter time spans. 

In summary, the information collected by the use of bioinformatics will lead to understanding of complex regulatory and disease pathways and will be helpful to design new treatment strategies. 

Figure 26.4. Molecular epidemiology diagram illustrating biomarkers in the disease pathway.

Medically, anions are of great importance in many disease pathways. Cystic fibrosis, a genetic illness affecting a significant proportion of society, is caused by misregulation of chloride channels (17). There is, therefore, a real need for selective halide detection, as established methods of chloride analysis are unsuitable for biological applications (18). Cancer is caused by the uncontrolled replication of polyanionic DNA. Anion-binding proteins have also been implicated in the mechanism of Alzheimer s disease (19). 

Eischer HP. Towards quantitative biology integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol Armu Rev 2005 11 1-68. 

In most studies, patients with rheumatoid arthritis have lower BMD and more fractures than do age-matched controls.Common disease pathways, inclnding proinflammatory cytokines and the OPG/RANK/RANKL system, may be responsible along with increased glucocorticoid use, hypogonadism, decreased activity, and increased fall risk. Patients taking glucocorticoids should be managed with calcium and vitamin D snpplementation plus a bisphosphonate. Otherwise, standard osteoporosis prevention and treatment interventions are recommended. 

The preclinical period as defined by DiMasi (107) begins at the point of synthesis of a compound. Since firms must screen multiple products to obtain a lead compound (399) and engage in basic research to understand disease pathways before synthesizing a new product, this period could understate the length of the true preclinical period. If the true mean preclinical... 

---